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1552-5260/ 2016 thtions and problematic diagnosis of vascular cognitive impairment (VCI) but none have been univer-
sally accepted. These criteria have not been readily comparable, impacting on clinical diagnosis rates
and in turn prevalence estimates, research, and treatment.
Methods: The Vascular Impairment of Cognition Classification Consensus Study (VICCCS)
involved participants (81% academic researchers) from 27 countries in an online Delphi consensus
study. Participants reviewed previously proposed concepts to develop new guidelines.
Results: VICCCS had a mean of 122 (98–153) respondents across the study and a 67% threshold to
represent consensus. VICCCS redefined VCI including classification of mild and major forms of VCI
and subtypes. It proposes new standardized VCI-associated terminology and future research priorities
to address gaps in current knowledge.
Discussion: VICCCS proposes a consensus-based updated conceptualization of VCI intended to
facilitate standardization in research.
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Cerebrovascular pathology, including microinfarcts,
lacunar infarcts, larger infarcts (of embolic or thrombotic
origin), and white matter lesions, is moderately to
strongly associated with cognitive decline [1–4]. Risk
factors include hypertension, diabetes mellitus,
smoking, atrial fibrillation, positive family history, age,
and hypercholesterolemia [5–7], with some risk from
APOE (ε4 allele) and MTHFR variants [8]. From the
time Hachinski et al. [9] proposed the term multi-
infarct dementia, numerous subsequent proposals have
tried to capture the clinical and etiologic complexity of
cognitive impairment caused by heterogeneous cerebro-
vascular disease (CVD) and pathologies [10–21]. These
include vascular dementia (VaD), vascular cognitive
impairment (VCI), subcortical (ischemic) VaD, and
vascular cognitive disorder (VCD), which have given
rise to multiple criteria and research guidelines
[13,17,19,21] that are not readily interchangeable
[22,23]. These factors contribute to variable prevalence
estimates in the literature, as do descriptions of clinical
manifestations. However, VaD, used to describe a
severe form in the continuum of VCI, is probably the
second commonest cause of dementia after Alzheimer’s
disease (AD), although as populations age this is likely
to increase [13,17,21,24]. Yet, incidence of dementia is
now decreasing in high-income countries, which may
partly relate to better CVD management [25]. CVD
commonly contributes to many forms of dementia,
including AD [26–28], and may be targeted with some
success [29], although further research into possible as-
sociations and causal relationships is needed. Studies
into causes and treatments of AD have greatly outnum-
bered those for VaD, partly by the availability of widely
used diagnostic criteria that continue to evolve [30] and
partly because of relatively more funding opportunities.
The lack of consensus criteria for diagnosis of VaD and
VCI has impeded sharing and comparison of data on a larger
scale, together with different specialties conducting narrow
focused research [31]. Greater harmony of approach within
the research community is needed [23,32]. A work group
convened by the NINDS-CSN made some progress [33],
producing detailed research recommendations for VCI.
However, their subsequent implementation and adoption re-
mains unclear.
The Vascular Impairment of Cognition Classification
Consensus Study (VICCCS) was designed to achieve a
broader consensus on the conceptualization of impairment
in cognition contributed by vascular pathology, for clin-
ical diagnosis and research. The aim was to provide
criteria that could be widely adopted within the field, to
underpin future research. VICCCS elaborated previous
work to inform the way forward, with input from a broad
spectrum of participants from the international research
community.2. Methodology
2.1. Participant selection
Previous attempts to develop consensus criteria were
largely based on comparatively smaller pools of opinion
leaders as part of organized meetings, conferences, or sym-
posia [33]. The intention for VICCCS was to draw on the
expertise of as many participants from as wide an array of
disciplines as possible. Participants for VICCCS were iden-
tified through unbiased review of published articles relating
to the concept or diagnosis of VaD/VCI in Pubmed, up to
August 2010. Several relevant research networks, including
the British Association for Stroke Physicians, Alzheimer’s
Disease Neuroimaging Initiative, and the European Alz-
heimer’s Disease Consortium were also invited.
Nine hundred five individuals were initially identified,
although it was not possible to find the contact details of
all these most likely because of the fact that some of the
source studies were published more than 20 years ago.
Further efforts to source these missing contact details were
made by inviting all potential participants who were con-
tacted to nominate and provide contact details for potentially
interested colleagues. This lead to 789 invitations initially
sent that generated a potentially 367 (46%) initially inter-
ested pool of international participants. Unlike previous en-
deavors, VICCCS used periodic internet-based surveys to
facilitate greater involvement and promote contributions
through providing sufficient time for reflection and re-
sponses that were given with anonymity and parity. The
study required considerable relevant clinical and research
knowledge and time commitment to complete multiple sur-
veys. Nonetheless, on average 122 participants contributed
to each round (range 98–153). Of these, a mean of 72%
(range 66%–76%) were clinicians with direct involvement
in clinical decision-making. The remainder were nonclinical
researchers. Average continental distributions were as fol-
lows: Europe 63%, North America 19%, South America
6%, Asia 9%, Africa 2%, and Australia 1%. Representation
in each round is detailed in Supplementary Table 1. Bar
graphs summarizing the professions and affiliations of the
authors are also provided in Supplementary Fig. 1. The
most common profession was Neurologist (46%) and the
most common affiliation was academic researcher (68%).
2.2. VICCCS Delphi process
We used a Delphi approach, an iterative structured pro-
cess involving a series of questionnaires with progressive
refinement of questions to achieve consensus among respon-
dents [34]. Only the independent moderator (O.A.S., who
did not herself participate in the survey) had access to iden-
tification details of the respondents. The anonymity of re-
sponses facilitated free expression of opinion throughout
the study. Structured feedback of responses after each round
informed the nature of subsequent questions, allowing unbi-
ased evolution of group judgments that may be difficult face
O.A. Skrobot et al. / Alzheimer’s & Dementia 13 (2017) 624-633626to face. A threshold of two-thirds agreement was chosen to
represent consensus [35] for issues refined through multiple
iterative rounds. Overall, six rounds of web-based surveys
were administered, approximately one every 2 months, to
maintain engagement. In the first two rounds, opinion was
canvassed on published criteria, their utility, and weak-
nesses. The remaining 4 rounds focused on addressing weak-
nesses and standardization of terminology. A summary of
the topics addressed in each round is provided as
Supplementary data.3. Results
3.1. VICCCS rounds 1 and 2: Critical appraisal of existing
proposals
In the first round, viewswere sought on themost important
issues to be resolved. The extent of use of existing criteria and
guidance, identified through literature review, were assessed.
We separated questions on “concept” articles, such as those
concerning the scope anddefinitions (n5 12), from thosepro-
posing diagnostic criteria (n5 15). Four articles covered both
aspects and were included in both sections. Round 1 gathered
participants’ views on these articles, but also invited addi-
tional suggestions for relevant articles that should be consid-
ered. Participants were asked to indicate their familiaritywith
the articles and score their usefulness, from “no longer rele-
vant” to “useful in all cases,” and to select three concepts
that could form the basis for wider acceptance. To reduce
bias in selection that might have been caused by definitions
that were older and perhaps more familiar, those selected
that scored “useful in most” or useful in all caseswere ranked
to represent whatwas a “considered useful vote.” The ranking
showed that more recently published concepts, even if not
widely known,were better regarded as a foundation for future
use. The collated scoreswere fed back to participants in round
2. Participants were then asked to reconsider all articles,
including those that might be less familiar, before again
ranking the criteria, after which low-ranking criteria would
be eliminated from further consideration.
Almost 60% of respondents ranked the VCI construct of
O’Brien et al. [13], representing a broad continuum fromBox 1
VICCCS consensus guiding principles of the refinement of the concept of V
1. Be broad and capture forms of vascular- or cerebrovascul
impairment or dementia.
2. Address shortcomings in both mild and severe forms of V
stage to another.
3. Recognize the importance of people who are at risk of VC
be contingent on some level of impairment.
4. Acknowledge that the classification of a patient with a mi
dictive of progression of the impairment to a more severe
5. Acknowledge that the classification of a patient with a mi
dictive of an eventual subtype of dementia.mild impairment to dementia, as the preferred conceptual
basis. The second and third ranked definitions, which ob-
tained 11% and 7% first-preference votes, also encompassed
VCI and associated concepts (Supplementary Fig. 2).
In addition, 78% of respondents felt that the definition of
VCI needed to be broader in scope. Therefore, the remaining
VICCCS rounds focused on obtaining consensus on a
revised conceptual model for VCI. The content of the subse-
quent rounds was based on responses to early round ques-
tions on definition, scope, sensitivity to subtypes of VCI,
and clinical utility.3.2. Rounds 3–6: Formulation of a revised VCI concept
In round 3, participants were asked to state their agree-
ment or disagreement with proposed guiding principles for
refinement of the concept of VCI. These had more than
94% agreement; amendments proposed by some participants
were reported for comment in round 4. Consensus guiding
principles are listed in Box 1.
Round 3 addressed three areas identified in round 2 as
meriting clarification or modification. Although 29% of re-
spondents thought the O’Brien construct did not need any
major improvement, a percentage of respondents felt
changes were desirable to its scope (13%), sensitivity to sub-
types (31%), and descriptiveness (39%). The subsequent
rounds worked toward improving these perceived limita-
tions. Forty-two percent of respondents thought the O’Brien
construct was not well aligned with clinical operational
criteria. These limitations were subsequently addressed in
a focused follow-on Delphi (VICCCS diagnosis) to develop
operational criteria (in preparation; however see Box 2 and
Supplementary data for some reported findings).
3.2.1. Scope
Approximately one-third (34%) of round 3 participants
suggested that other potential mechanisms of VCI should
be included in the revised concept. In round 4, participants
were asked to vote on inclusion of the suggested mecha-
nisms. There was consensus that the additional mechanisms
listed in Table 1 should be included within the revisedCI.
ar-related damage that are likely to contribute to cognitive
CI and means to assess the transition of patients from one
I; however, their consideration under this construct should
ld form of VCI (i.e., non-dementia) is not necessarily pre-
form of VCI (i.e., dementia).
ld form of VCI (i.e., non-dementia) is not necessarily pre-
Box 2
VICCCS proposed definitions of major VCI (VaD) subtypes.
Post-stroke dementia: A patient described as having PSD may or may not have presented evidence of mild cognitive
impairment before stroke. The patient may exhibit immediate and/or delayed cognitive decline that begins after, but within
6 months, of stroke, that does not recover. PSD results from different vascular causes and changes in brain. It includes cases
with multiple corticosubcortical infarcts, strategic infarcts, subcortical ischemic vascular dementia, and various forms of
neurodegenerative pathology, including AD, which develop within 6 months of stroke*. This temporal basis for cognitive
decline after stroke differentiates PSD from other forms of major VCI (VaD).
Mixed dementias: A standalone umbrella subgroup termedmixed dementias includes all the phenotypes specified for each
combination, that is VCI-AD, VCI-DLB, so forth. It is recommended that a patient is referred to as having “VCI-AD”, ac-
cording to the phenotypes present, rather than less specific mixed dementia, for example. Where discrimination is possible,
the order of terms should reflect the relative contribution of the underlying pathology, that is AD-VCI or VCI-AD.
Subcortical ischemic vascular dementia (SIVaD):y Small-vessel disease is the main vascular cause of SIVaD. Lacunar
infarct and ischemic white matter lesions are the main type of brain lesions, which are primarily located subcortically. It
incorporates the overlapping clinical entities of Binswanger’s disease and the lacunar state.z
Multi-infarct dementia (MID): “MID relates to the involvement, and likely contribution, ofmultiple large cortical infarcts in the
development of dementia.”x The previously mentioned VICCCS definition of PSD is built on the definition of O’Brien et al. [13].
*Because a key facet of the definition of PSD is a time component of the appearance of decline within 6 months of having a stroke that does not recover,
then irrespective of the presence or absence or comorbid neurodegenerative pathology, the aspect of time should be the primary variable for delineating
between PSD (with or without neurodegenerative pathologywhich if present should be described) andmixed pathology (where the contributing components
are described). In other words, PSD and mixed dementias could both have mixed pathology but PSD is recognized by its more acute presentation.
yAs part of the efforts in VICCCS to standardize the nomenclature and abbreviations to be used in the future, VICCCS diagnosis participants were asked
which abbreviation, from those most commonly used for SIVaD, should be taken forward. Initially, no consensus was reached (SIVaD, 36%; SIVD, 23%;
SiVaD, 19%; SiVD, 4%, with 18% stating no preference) but in the subsequent round, where participants were asked to choose their preference from the two
most favored abbreviations from round 4, most support was for SIVaD (65%) and therefore adopted.
zNinety-nine percent of respondents asked about this definition in the VICCCS diagnosis study supported this original definition [11] of SIVaD, whereas
92% supported it as a diagnostic category. Seventy-six percent of respondents stated that they would use this term clinically.
xSixty-nine percent of VICCCS diagnosis respondents agreed thatMID should be a diagnostic category; however, opinion was split on the use of this term
in the clinical setting,with only 52% in favor of it. Therewas a consensus (72%) support for the original definition ofMIDbyHachinski et al. [9].MID reflects
the traditional view that multiple large cortical infarcts are required for dementia to develop; however, the most frequent objection was use of the word
“required.” Therefore, to give opportunity for this objection to be considered, a modified definition was also presented along with the original definition for
participants to state their support in the subsequent round. The modified definition, as given above, proposed received a consensus support (72%).
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as to what should constitute the arteriopathies subgroup
(proposed in the O’Brien construct); however, in VICCCS,
specific arteriopathies are a descriptive term of cause rather
than a subgroup (Table 2).
3.2.2. Sensitivity to subtypes
TheO’Brien construct was thought by 31% of respondents
to be limited in capturing subtypes of VCI. Although it
acknowledged rare hereditary disorders cause VCI, the
construct focused mainly on sporadic forms of VCI.
Seventy-eight percent of VICCCS respondents suggested
that both hereditary (i.e., “type I” or “familial” VCI) and spo-
radic (i.e., “type II”) should be encompassed within VCI. In
round 4,most (85%) respondents preferred the terms sporadic
and familial to be used as descriptive information for various
forms of VCI rather than to define separate categories.
The proposed subtypes of the revised concept of VCI ac-
cording to the VICCCS are depicted in Fig. 1.
3.2.2.1. Mild and major VCI (VaD)
In the O’Brien construct, VaD was used as an umbrella
term for subgroups of severe forms of VCI. Round 3 partic-ipants were asked whether the term VaD was still useful. No
clear consensus emerged, although a small majority (56%)
favored its continued use. However, the timing of this
VICCCS round coincided with the drafting of the fifth edi-
tion of Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-5), widely used by clinicians worldwide. The
draft DSM-5 proposal was that VaD or major VCDs [36]
be shown in parentheses with the description “major neuro-
cognitive impairment because of vascular disease” as a clas-
sification group for severe forms of impairment heretofore
referred to as VaD [37].We therefore sought VICCCS partic-
ipants’ views on the use of the terms “mild” and “major” in
relation to VCI. Although only 39% of round 4 respondents
were aware of the draft DSM-5, 71% agreed that the revised
VCI concept should use the terms mild and major to align
VICCCS recommendations with DSM-5. In round 5, a
71% majority supported the terminology “mild forms of
VCI” and “major forms of VCI (VaD).”
3.2.2.2. Further subtyping of mild forms of VCI
Subtyping of mild forms of VCI was addressed in
rounds 3 to 6. Most respondents (68%) were in favor of
specifying subtypes. However, in response to a separate
Table 1
Clarification of the possible mechanisms of cause of either sporadic or
hereditary VCI
Mechanisms of cause suggested by VICCCS
participants Percentage support
Cerebral amyloid angiopathy 93
Mixed forms, any neurodegenerative diseases
with CVD (e.g., DLB with CVD)
93
White matter hyperintensities 93
Microbleeds/microhemorrhages 89
Microinfarcts 89
Arteritis/vasculitis, including both local and
systemic inflammatory syndromes
82
Subdural or subarachnoid hemorrhage 70








Abbreviations: CVD, cerebrovascular disease; DLB, dementia with Lewy
bodies; VCI, vascular cognitive impairment; VICCCS, Vascular Impairment
of Cognition Classification Consensus Study.
NOTE. Participants were given the opportunity to propose additional
causative mechanisms to those previously listed in the O’Brien concept
[13]. Percentage support from respondents in the final round is detailed.
Those highlighted in italics reached consensus support of 67% and therefore
are recommended.
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ing evidence and was premature, and no subtype option
could be agreed. Further detail of this is provided in the
Supplementary Materials. VICCCS propose that mild
VCI is not subtyped at this time until research provides
better justification.Table 2
VICCCS-recommended subtypes and descriptive terms











Abbreviations: AD, Alzheimer’s disease; VaD, vascular dementia; VCI, vascula
sification Consensus Study.
NOTE. Mild VCI, poststroke dementia, multi-infarct (cortical), subcortical isc
italics fall under the umbrella term major VCI (VaD). Agreed revised definitions
*Specific arteriopathies were agreed in a separate question for two rounds to inc
sickle cell disease, cerebral autosomal-dominant arteriopathy with subcortical infar
arteriopathy with subcortical infarcts and leukoencephalopathy [CARASIL]), sma
immunological vasculitis, Moyamoya disease, and intracranial atherosclerosis.
yA revised holistic subtype of mixed dementias was developed and agreed over
agreed descriptive terms include strategic infarct, hypoperfusion, hemorrhagic, an
zVasculitis, which was not originally part of the O’Brien concept, was also dis
O’Brien concept classification and causes of sporadic VCI [13] are listed for com3.2.2.3. Further subtyping of major forms of VCI (VaD)
In round 3, respondents were asked to decide which sub-
types of dementia proposed by O’Brien et al. should be
recognized in VICCCS. Variable levels (81%–50%) of
agreement were found. In round 4, most respondents
(94%) agreed that this lack of consensus might be over-
come if it were possible to avoid mixing site, severity,
and mechanism. Ninety-six percent supported an effort to
develop a more systematic stepwise approach toward sub-
typing based on VICCCS proposed categories of Location,
Etiology, Domains (affected), and Severity, provisionally
named “LEDS” criteria. With this in mind, participants
were asked which of the O’Brien subtypes allowed for
more mutually exclusive grouping of patients or might be
considered better suited as descriptive terms for either
the “mechanism” or “location” of damage. The subtypes
“specific arteriopathies,” “hemorrhagic” and “hypoperfu-
sion” were not supported as standalone subtypes (13%–
18%) and thus are recommended as descriptive terms of
causal mechanisms in VCI. The remaining subtype terms
received variable support between rounds. Round 6
collected a definitive decision, with terms that did not
achieve majority (67%) support to be descriptors. “Subcor-
tical ischemic” (83%) and “multi-infarct (cortical)” (74%)
were supported as subtypes of major VCI (VaD). As in
earlier rounds, poststroke dementia (PSD) was supported
(73%) as a subgroup and 86% thought it also helpful for
clinical diagnosis. In contrast, despite near threshold sup-
port (66%), for consistency “strategic infarct dementia”
will also be proposed as a descriptive term for VCI. Addi-
tional suggestions for standalone subtypes of VCI were
also invited. None of these were supported but “vasculitis”O’Brien concept classification and causes of sporadic VCI
Poststroke dementia
VaD





Dementia caused by specific arteriopathies
Mixed AD and VaD
Vascular mild cognitive impairment
r cognitive impairment; VICCCS, Vascular Impairment of Cognition Clas-
hemic, and mixed dementias are agreed subtypes in the VICCCS. Those in
of subtypes are detailed in Box 2.
lude genetic, hereditary and developmental anomalies (e.g., Fabry’s disease,
cts and leukoencephalopathy [CADASIL], and cerebral autosomal recessive
ll-vessel disease from chronic hypertension and/or diabetes, inflammatory/
the course of number of rounds to replace “mixed AD and VaD.” VICCCS
d specific arteriopathies.
cussed in more detail as being an important descriptive term. The original
parison.
Fig. 1. Revised conceptualization of VCI in VICCCS. Subtypes of VCI are divided according to the level of VCI impairment into mild VCI and major VCI
(VaD). Mild VCI is not further subdivided at this time. Major VCI (VaD) is classified into four main subtypes as depicted. The 6 month temporal basis (denoted
by the hashed box) for cognitive decline after stroke differentiates poststroke dementia (PSD) from other forms of major VCI (VaD). PSD and mixed dementias
are further delineated if a comorbid neuropathology is present (N.B. AD and dementia with Lewy bodies (DLB) are given as examples, with # denoting other
possible combinations). Subcortical ischemic VaD or multi-infarct (cortical) dementia subtype cases with these specific types of dementia alone, however cases
also presenting with any other neurodegenerative pathology would then be categorized as mixed dementias (dashed arrows) according to the comorbidities pre-
sent. Abbreviations: AD, Alzheimer’s disease; VaD, vascular dementia; VCI, vascular cognitive impairment; VICCCS, Vascular Impairment of Cognition Clas-
sification Consensus Study.
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(Supplementary Table 2). The resultant VICCCS-




Mixed dementia and its definition in clinical practice
and research were identified as needing elucidation
from the earliest rounds, with 97% of respondents favor-
ing change to the traditional imprecise usage. In the final
Delphi round, 95% of respondents agreed with a pro-
posed solution to the differences in opinion on the term
(detailed in Supplementary Material). “Mixed demen-
tias” proposed should serve only as an “umbrella” term
for subtypes of major VCI (VaD) under which all pheno-
types present would be specified. Patients would be
referred to as having for example; VCI-AD, VCI–demen-
tia with Lewy bodies, so forth according to whatever de-
mentia comorbidities presented. A large number of
respondents (81%) endorsed this approach for both
research and clinical applications, and consensus (68%)
was that the order of abbreviations should reflect
the relative contributions of the comorbidities, as far as
practicable.3.2.3.2. Poststroke dementia
There was consensus for the term PSD to be used in
research (73%) and clinical (86%) contexts, but no
consensus (63%) around how PSD was previously
described, which we had tried to address in later rounds
and continued to do in VICCCS diagnosis. Related issues
thought necessary to clarify PSD, including evidence of
cognitive impairment before stroke and timeframes for the
emergence of PSD, are detailed in Supplementary
Material. VICCCS consensus (78%) views on delineation
of PSD are detailed in Box 2 and Fig. 1. Of note is the tem-
poral association between cognitive decline and stroke dif-
ferentiates’ PSD from other forms of major VCI (VaD),
that is, cognitive impairment within 6 months of having a
stroke would be the determining factor for a diagnosis of
PSD.
Consensus proposed definitions for major VCI (VaD)
subtypes (PSD, mixed dementias, subcortical ischemic
VaD, and multi-infarct dementia) are presented in Box 2.4. Discussion
VICCCS has provided revision and consensus-based
elaboration of the construct of VCI in most areas addressed.
Lack of consensus in some areas was mainly because of a
O.A. Skrobot et al. / Alzheimer’s & Dementia 13 (2017) 624-633630few research data available at the time, for example, the sub-
categorization of mild forms of VCI. VICCCS showed that
although half of the respondents wanted to lessen the over-
emphasis on memory-impairment in the conceptualization
of VCI, two-thirds acknowledged the benefit in the amnestic
separation to facilitate alignment with current formats used
for AD and mild cognitive impairment. Thus, subtypes of
VCI require more research-based justification.
Definition of more homogeneous groups was supported
for major VCI—also important for clinical trial design. Clin-
ical diagnosis of coexisting pathologies remains a challenge.
Previous definitions of mixed dementia were not greatly sup-
ported in VICCCS, partly because of dissatisfaction with the
overemphasis of AD (see Supplementary Material). When
the study concluded, a revised concept of the most favored
definition (25% support) has been published for “mixed
AD” [30] that does provide separate criteria for coexisting
CVD and Lewy body pathology, however does not differen-
tiate these by terminology. VICCCS proposes in mixed de-
mentias and PSD that all phenotypes identified should be
specified, depending on whatever dementia-related comor-
bidities are present, wherein the order of abbreviations re-
flects the perceived relative contributions. Improvements
to the practicalities and accuracy of this would be important
aspects of any future operational diagnostic protocols,
whereas ongoing research in biomarkers may be helpful.
Recent evidence lends weight to this approach, where
subcortical VaD can be identified in an outpatient memory
clinic setting according to the neuropsychological features
and CSF-biochemical markers distinct from those of AD
[38]. Box 3 summarizes this and other areas for future
research either proposed or reflected in responses from
VICCCS.
VICCCSwas conducted between 2010 and 2013 that coin-
cided with the development of DSM-5 [39] and International
Society for Vascular Behavioral and Cognitive Disorders
(VASCOG) criteria for VCD [36]. VICCCS participants
were given the opportunity to provide collective feedback
on draft DSM-5 proposals that were made available beforeBox 3
Potential areas for future research as proposed directly or identified from r
1. Evidence-based studies to support further subdivision of
2. Develop a more systematic stepwise approach toward su
gories of location, etiology, domains (affected), and sever
3. Investigation of factors that determine immediate or dela
4. Investigation of factors (e.g., time to onset, biomarkers, cog
PSD with other causes of VCI or nonvascular dementias.
5. Further elucidation to improve phenotyping of relative co
VCI or VCI-AD in mixed dementias, or other neurodege
disorders that copresent with CVD.
6. Further exploration of the utility and validity of the traditio
of major VCI (VaD) or as a complementary descriptive t
(VaD)its finalization. This was enabled through a tailored survey
developed (by O.A.S.) in consultation with P.S. acting on
behalf of the DSM-5 Neurocognitive Disorders Work Group
and was prompted by their online request for input from the
clinical research community into the refinement process.
Awareness among VICCCS participants of this request was
relatively modest, demonstrating a need for wider advertise-
ment of such consultations in future. VICCCS participants
agreed that the mild and major terminologies proposed in
DSM-5 were helpful and similarly should be adopted in
VICCCS.
In relation to the subsequent published criteria (in 2014)
for VCDs, VICCCS had previously explored but was not
supportive of this concept and the use of this term VCD
[11,17]. However, the VASCOG criteria are also reported
to be aligned with DSM-5 [36].4.1. Considerations of the Delphi process on VICCCS
outcomes
A key principle of the Delphi method is that decisions
from a structured specialist group of individuals are more ac-
curate. The use of online surveys in VICCCS, to avoid
scheduling constraints of a physical meeting, facilitated
the inclusion of an unprecedented large number of interna-
tional participants who have enriched discussions. The ano-
nymity offered by Delphi reduced the potential for any
individuals to dominate direction of discussions. Further-
more, in combination with the repeated group feedback,
the anonymity allowed contemplation, review of initial judg-
ments, and scope for participants to freely change opinions,
all of which promoted the generation of consensus [34,40].
The use of specific published articles helped to focus the
discussion points and in some cases, increased awareness
of previous studies, aiding more-informed decision making.
After the initial rounds, structured, mostly closed questions
were mainly used to ensure continued focus when some
feedback was possible, in the primary discussion of topics.
This sometimes extended the duration of the study andesponses from the VICCCS.
mild VCI.
btyping of patients based on new VICCCS proposed cate-
ity.
yed onset of VCI in PSD patients.
nitive parameters) that may better delineate comorbidity of
ntribution of the co-occurring pathology, for example, AD-
nerative diseases (e.g., Parkinson’s disease) or psychiatric
nal termmulti-infarct dementia as either a specific-subtype
erm alongside the newly proposed subtypes of major VCI
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mixed dementias and PSD. Yet the extended debate was use-
ful but increased risk of participant attrition, and variation in
respondent numbers in each round did variably impact on the
relative contribution of each respondent toward consensus.
However, most topics were dealt with over multiple rounds
giving many opportunities to confirm the consensus view.
The maintenance of a high number of participants
throughout the study provides assurance that a consensus
concept of VCI has been realized, although by definition
the consensus was based on a majority view.5. Conclusions
VICCCS presents a new consensus-based set of guide-
lines supported by a large international pool of researchers.
These guidelines have drawn on, expanded, and refined pre-
vious efforts to improve and clarify the conceptualization of
VCI. It is anticipated that VICCCS guidelines will be widely
adopted in the community to increase the levels of consis-
tency and standardization in undertaking VCI research.
This should significantly enhance the interpretation and
comparison of findings across studies and support the likeli-
hood of more large-scale collaborative research that will be
vital to help overcome historical limitations posed by the
prevalence of VCI.Acknowledgments
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1. Systematic review: Capturing the complexity
involved in vascular cognitive impairment (VCI)
has given rise to various terms such as multi-infarct
dementia, vascular dementia, subcortical (ischemic)
vascular dementia, VCI, and vascular cognitive dis-
orders. These terms were used as search-terms in
Pubmed for relevant published reports (by August
2010). The authors list identified potential study
participants and a Steering Group. Twelve concept
articles and 15 articles proposing diagnostic criteria
were used in the Delphi study.
2. Interpretation: This process resulted in the formation
of new consensus-based guidelines for VCI that have
drawn on and refined previous initiatives. High levels
of participation by the research community should
ensure these guidelines will be more widely
endorsed.
3. Future directions: Key research priorities include
evidence-based studies to (1) determine appropriate
subdivision of mild VCI and (2) improve phenotyp-
ing of the co-occurring pathology in mixed de-
mentias, and other neurodegenerative diseases or
psychiatric disorders that copresent with cerebro-
vascular disease.References
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